Skip to main content
    G

    GT Biopharma Inc (GTBP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.50
    -0.30 (-4.41%)

    Market Cap: $12.76M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    52%(12/23)
    Avg Surprise
    -479.03%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-2.50
    Range$-2.50 - $-2.50
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-2.00-25.0%
    60d ago$-2.00-25.0%
    30d ago$-2.00-25.0%
    7d ago$-2.00-25.0%
    Current$-2.50
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-8.09
    Range$-8.09 - $-8.09
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-8.09---
    Sep 26EST
    		-$-2.50---
    Jun 26
    Reported Aug 14
    		$-0.12$-0.08-50.00%Miss+78.2%
    Mar 26
    Reported May 15
    		$-0.11$-0.08-37.50%Miss+85.5%
    Dec 25
    Reported Mar 2
    		$-121.00$-5.50-2100.00%Miss-7189.2%
    Sep 25
    Reported Nov 14
    		$-0.83$-0.38-118.42%Miss+45.8%
    Jun 25
    Reported Aug 14
    		$-0.55$-0.68+19.12%Beat+74.6%
    Mar 25
    Reported May 15
    		$-0.76$-0.64-18.75%Miss+53.7%
    Dec 24
    Reported Feb 21
    		$-1.66$-1.55-7.10%Miss+24.2%
    Sep 24
    Reported Nov 14
    		$-1.53$-2.70+43.33%Beat+28.2%
    Jun 24
    Reported Aug 14
    		$-2.17$-2.70+19.74%Beat+14.7%
    Mar 24
    Reported Apr 4
    		$-1.64$-2.70+39.26%Beat+42.5%
    Dec 23
    Reported Mar 26
    		$-2.19$-2.70+18.89%Beat-1116.7%
    Sep 23
    Reported Nov 1
    		$-2.13$-3.30+35.45%Beat+67.8%
    Jun 23
    Reported Aug 7
    		$-2.54$-3.60+29.44%Beat+11.2%
    Mar 23
    Reported May 15
    		$-2.85$-4.35+34.48%Beat-1576.5%
    Dec 22
    Reported Mar 30
    		$-0.18$-0.17-5.88%Miss+98.9%
    Sep 22
    Reported Oct 31
    		$-6.61$-3.30-100.30%Miss-16.2%
    Jun 22
    Reported Aug 11
    		$-2.86$-5.40+47.04%Beat+27.0%
    Mar 22
    Reported May 16
    		$-0.17$-0.31+45.16%Beat+99.7%
    Dec 21
    Reported Mar 28
    		$-15.76$-6.30-150.16%Miss-364.9%
    Sep 21
    Reported Nov 10
    		$-5.69$-7.05+19.29%Beat-14125.0%
    Jun 21
    Reported Aug 23
    		$-3.92$-7.65+48.76%Beat-3166.7%
    Mar 21
    Reported Apr 16
    		$-54.90$-9.90-454.55%Miss-274400.0%
    Dec 20
    Reported Dec 31
    		$-3.39$-0.04-8375.00%Miss-16850.0%
    Sep 20
    Reported Nov 13
    		$-0.04N/AN/ABeat+92.2%
    Jun 20
    Reported Aug 14
    		$-0.12N/AN/ABeat-140.0%
    Mar 20
    Reported May 15
    		$-0.02N/AN/ABeat+77.8%
    Dec 19
    Reported Mar 27
    		$-0.02N/AN/ABeat+75.0%
    Sep 19
    Reported Nov 14
    		$-0.51N/AN/ABeat+89.1%
    Jun 19
    Reported Aug 14
    		$-0.05N/AN/ABeat+72.2%
    Mar 19
    Reported May 15
    		$-0.09N/AN/ABeat+55.0%
    Dec 18
    Reported Mar 29
    		$-0.08N/AN/ABeat+33.3%
    Sep 18
    Reported Nov 15
    		$-4.70N/AN/ABeat+42.3%
    Jun 18
    Reported Aug 14
    		$-0.18N/AN/ABeat+99.9%
    Mar 18
    Reported May 15
    		$-0.20N/AN/ABeat+99.8%
    Dec 17
    Reported Mar 1
    		$-0.12N/AN/ABeat+100.0%
    Sep 17
    Reported Nov 14
    		$-8.15N/AN/ABeat-
    Jun 17
    Reported Aug 11
    		$-138.55N/AN/ABeat-
    Mar 17
    Reported Apr 28
    		$-87.40N/AN/ABeat-
    Dec 16
    Reported Mar 31
    		$-448.21N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.00EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-113.50%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio2.61xQuick Ratio2.61x
    Trading Statistics
    Beta0.85Avg Volume83.46K
    52-Week High$28.7552-Week Low$4.91

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.34
    SMA 20$6.74
    SMA 50$7.16
    SMA 200$10.60
    EMA 10$6.52
    EMA 20$6.71
    EMA 50$7.33
    EMA 200$12.61

    MACD

    Line: -0.28Signal: -0.30Hist: 0.02

    ADX

    ADX: 40.9+DI: 14.9-DI: 6.5

    Aroon & PSAR

    Aroon Up16.0
    Aroon DownN/A
    PSAR$9.51

    Bollinger Bands

    Upper Band$7.73
    Lower Band$5.75
    %B Position2942%(Upper)
    Band Width0.38

    RSI (14-Day)

    Neutral
    46.5

    Momentum Oscillators

    Stoch %K56.2
    Stoch %D42.5
    Williams %R-58.8
    ROC (10d)-5.5%
    Momentum-0.38
    CCI (20d)1.5
    MFI (14d)49.4

    Volatility Measures

    ATR (14d)$1.75(26.9%)
    StdDev (20d)0.50
    Hist Vol76.7%(High)

    Volume Flow

    VWAP$6.78
    OBV101.0M
    AD Line148.6B
    CMF (20d)-0.097

    Volume Metrics

    Avg Vol (20d)48.8K
    Vol Ratio0.6x
    VWMA (20d)$6.91

    Pivot Points

    R3$7.62
    R2$7.33
    R1$7.07
    Pivot Point$6.78
    S1$6.52
    S2$6.23
    S3$5.97

    Advanced Oscillators

    TSI-9.09
    Ultimate Osc44.0
    KST-115.45

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Operating Expenses$4.51M$2.85M$5.59M$3.38M$1.51M$1.93M$3.76M$3.60M$3.91M$3.09M$3.17M$3.12M
    R&D$1.05M$413,000$1.38M$634,000$363,000$1.10M$1.93M$1.31M$1.78M$777,000$1.36M$1.36M
    SG&A$3.46M$2.44M$4.22M$2.75M$1.15M$833,000$1.83M$2.30M$2.12M$2.31M$1.81M$1.76M
    Operating Income$-4,512,000$-2,848,000$-5,595,000$-3,382,000$-1,513,000$-1,932,000$-3,763,000$-3,604,000$-3,906,000$-3,091,000$-3,168,000$-3,122,000
    Interest Income$58,000$67,000$17,000$36,000$38,000$32,000$59,000$96,000$105,000$142,000$180,000$216,000
    Interest Expense$64,000$63,000$1.13M$0$0$-998,000$12,000$0$0$0$1,000$0
    Income Before Tax$-4,518,000$-2,833,000$-23,031,000$8.30M$-30,169,000$-776,000$-3,775,000$-3,411,000$-3,710,000$-2,266,000$-2,962,000$-2,416,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-4,518,000$-2,833,000$-23,031,000$8.30M$-30,169,000$-776,000$-3,775,000$-3,411,000$-3,710,000$-2,266,000$-2,962,000$-2,416,000
    EBITDA$-4,512,000$-2,837,000$-21,923,000$8.26M$-30,207,000$-1,806,000$-3,834,000$-3,507,000$-3,815,000$-2,408,000$-3,142,000$-2,632,000
    EBIT$-4,512,000$-2,837,000$-21,923,000$8.26M$-30,207,000$-1,806,000$-3,834,000$-3,507,000$-3,815,000$-2,408,000$-3,142,000$-2,632,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GTBP

    News

    GT Biopharma proposes 250 million shares and dilution risk rises for GT Biopharma stock

    GT Biopharma is proposing to increase its authorized common shares from 25 million to 250 million, which will be voted on by stockholders on November 11, 2026. This move could dilute earnings per share and voting rights...

    ad-hoc-news.de•10/16/26•Bearish

    GT Biopharma registers 13.5M shares: what it means for GT Biopharma stock

    GT Biopharma has registered up to 13.5 million common shares for resale, significantly higher than its 2 million shares currently outstanding...

    ad-hoc-news.de•10/13/26•Somewhat-Bearish

    Form S-1 GT Biopharma Inc For: 9 October By Investing.com

    This article announces that GT Biopharma Inc. filed a Form S-1 on October 9. The filing pertains to the company and is part of the financial news provided by Investing.com. The information is presented without further...

    Investing.com Nigeria•10/9/26•Neutral

    GT Biopharma regains Nasdaq compliance: what it means for GT Biopharma stock

    GT Biopharma has regained compliance with Nasdaq's minimum bid requirement after its stock closed above $1.00 for ten consecutive business days. This removes the immediate threat of delisting but does not alter...

    AD HOC NEWS•10/5/26•Somewhat-Bullish

    GT Biopharma sells USD 7.75 million: what it means for GT Biopharma stock

    GT Biopharma recently sold $7.75 million in an equity offering, with an additional $31.21 million remaining to be sold. The company also regained compliance with Nasdaq's minimum bid requirement after its stock closed...

    AD HOC NEWS•10/1/26•Neutral

    GTBP Valuation and Fair Value

    P/E
    -0.0x
    Forward P/E
    17.3x
    PEG
    1.1x
    P/B
    2.8x
    See GNG's fair value

    GTBP Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -113.5%

    GTBP Competitors

    CompanyTicker
    Femasys IncFEMY
    Anebulo Pharmaceuticals IncANEB
    Biofrontera IncBFRI
    Synlogic IncSYBX
    Tvardi Therapeutics, Inc.TVRD
    Tharimmune Inc.THAR
    Vyome Holdings, Inc.HIND
    Pluri Inc.PLUR

    Sector: Healthcare

    GTBP Bull Case vs Bear Case

    Bear case

    • GTBP beat EPS estimates in 25.0% of its last 8 reported quarters.

    GTBP Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -283.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-2.50
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About GTBP

    Does GTBP pay dividends?

    GT Biopharma Inc (GTBP) does not currently pay a regular dividend.

    What is GTBP's market cap?

    GT Biopharma Inc (GTBP) has a market capitalization of $12.76M with a current stock price of $6.50.

    Related stocks

    Sector: Healthcare

    All stocks starting with G

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In